Logo Image

Manufacturing

Latest News

Standard Quality Control Certification Assurance Guarantee Internet Business Technology Concept | Image Credit: ©Sikov -stock.adobe.com
May 11th 2026
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 1: Regulatory Framework, Inspectional Findings, and Documentation System Evaluation

This article evaluates a structured, risk-based framework for the development, execution, and life cycle governance of master production and control records and batch production and control records systems aligned with current good manufacturing practice requirements and internationally harmonized pharmaceutical quality system guidance.

As global health standards and expectations regarding sanitary manufacturing increase, advancements in aseptic filling remain a top priority for modern pharmaceutical filling lines. The pharmaceutical industry has recently shifted toward biologics, high-potency compounds, cell-based therapies, and more complex combination products. As a result, the demands placed on aseptic filling lines are increasing rapidly, and regulatory frameworks such as European Union (EU) Good Manufacturing Practice (GMP) Annex 1, among others, further raise expectations around contamination control. To meet these expectations, filling lines must conform to stringent sterility standards while maintaining operational flexibility and efficient throughput. What it means for a filling line to be “sterile” has changed over the years. Modern filling lines are expected to accommodate diverse formulations and container formats while minimizing variability and the need for human intervention. Achieving this balance is no easy feat: It requires engineering expertise, integrated isolator technology, and automation strategies designed with both current regulatory expectations and future manufacturing realities in mind. The modern aseptic filling landscape Much of the current bio/pharmaceutical filling landscape revolves around isolators that can operate with no need for human intervention. Manufacturers are seeking partners capable of supplying integrated aseptic systems complete with washing, sterilization, depyrogenation, filling, sealing, and environmental control across liquids, powders, suspensions, and biologics. Manufacturers must supply product contact equipment while having the know-how to design, test, and validate systems to ensure their operational functionality and reliability. These developments all result from substantial advancements in filling line technology and the general approach to aseptic processing. Isolator-based filling lines have become the standard for high-risk aseptic processing. By physically separating operators from the critical processing environment, isolators significantly reduce contamination risk while ensuring compliance with international regulations (such as EU GMP Annex 1, FDA, Pharmaceutical Inspection Co-operation Scheme, and ISO 14644). Human intervention carries too much risk; therefore, one primary goal for modern filling line systems is to reduce the amount of necessary human input. Isolator-based filling lines solve this crucial problem. As for contamination control, suppliers must provide optimum sterile conditions for the product stream throughout the filling process. Manufacturers often rely on clean-in-place and sterilize-in-place technology wherever possible. Isolator systems must be constructed using optimal engineering standards and components, while ensuring optimal processing by installing analytical technology, including automated environmental monitoring and continuous particulate air quality assessment. There is no more difficult challenge in aseptic processing and building environmental control systems than achieving perfect sterility assurance and containment of pharmacologically potent products simultaneously. Isolators must be manufactured with both containment and sterility assurance in mind. Companies can address this problem by manufacturing isolators with air-handling systems that use either a single-pass or recirculating air supply. Manufacturers that utilize this technology have the requisite flexibility without losing the ability to tailor and tweak their systems as needed—a necessary attribute given the demand placed on aseptic filling lines today. Filling line challenges, modern solutions Lyophilized vs nonlyophilized products One evident distinction in aseptic filling line design lies between lyophilized and nonlyophilized products. Lyophilization, or freeze‑drying, is a critical stabilization step in aseptic processing, particularly for products that are unstable in liquid form. Nonlyophilized products are typically sterilized via filtration of solutions in which bioburden has been well controlled; however, many substances require lyophilization in order to ensure product stability over a suitable shelf life. Although lyophilization is a must for many products, the process carries an elevated risk of microbial contamination—particularly during transport, loading, and unloading of partially stoppered containers. Historically, given the additional risks of manual handling by human operators, lyophilization has been considered by most experts to be the most contamination-prone operation in aseptic processing. Environmental separation, coupled with automation, is necessary to provide the most reliable risk abatement for transporting filled and partially stoppered containers to the lyophilizer. In practice, this means automatically loading containers without any direct human intervention. Lyophilization also introduces efficiency concerns, as processing time increases with the lyophilization process itself, leading to potentially reduced throughput. For maximum uptime and efficiency, optimized process control, minimal required maintenance, simplified changeover, and extremely high reliability are absolute musts. Of course, compliance depends on strictly following industry regulations as outlined in EU Annex 1 and FDA’s aseptic cGMP guidance. Containers must be fully closed/sealed under Grade A/ISO 5 conditions, and any secondary closure, such as an aluminum vial cap, must be installed under ISO 5 conditions. Containers must be assessed properly following the lyophilization cycle to ensure proper seal. Any improperly sealed containers must be detected, automatically segregated, electronically documented, and controlled. Ultimately, modern best practice for aseptic processing calls for fully automated systems capable of transporting filled containers, loading lyophilizers, unloading them after the cycle, and undertaking electronic optical inspection to identify defects. All this should be accomplished automatically without human intervention. This degree of automation may seem like a tall order for manufacturers in terms of cost, but the benefits are many. Close attention to engineering detail and thorough quality systems to maintain equipment performance and reliability ensure that complex automated processes can substantially reduce downtime and product risk. Aseptic health care product manufacturers must provide the highest possible sterility assurance for high-patient-risk products, such as oncology treatments, high-risk products, and biological products that are most susceptible to microbial contamination. Performance can be optimized through high-capability equipment that eliminates risk in the lyophilization process by preventing direct human intervention while reducing line stoppages and optimizing both uptime and product yield. In this way, manufacturers can significantly increase efficiency and flexibility by delegating personnel to higher-value tasks. Flexible formats and syringes Beyond traditional vial lines, many manufacturers now expect filling platforms to handle flexible or combination (kit) drug delivery presentations and a mix of ready‑to‑use and bulk syringe components. This can be addressed by integrating form‑fill‑seal systems within isolators for complex flexible packages and by designing equipment that can aseptically process both nested ready-to-use syringes and bulk components that require in‑line washing, sterilization, and assembly. Together, these capabilities support combination products and evolving delivery systems without sacrificing aseptic sterility assurance, high yield, or changeover efficiency. Batch variability Batch variability is a persistent and complex challenge for aseptic filling lines. As the pharmaceutical industry continues to focus on biologics and high-potency drugs, both often produced in increasingly small or personalized batch sizes, maintaining consistency between batches becomes difficult yet crucial. Batch variability can stem from multiple sources, including differences in raw material properties, fluctuations in process parameters, equipment wear or calibration drift, frequent line changeovers, and residual human intervention. Even when materials and components fall within specification, subtle differences in viscosity, particulate load, or container characteristics can influence filling accuracy, stoppering performance, and overall sterility assurance. In aseptic environments, the consequences of batch variability increase 10-fold. Unlike processes that rely on terminal sterilization, aseptic filling depends entirely on process control and environmental integrity. Deviations in fill volume, container-closure integrity, or environmental conditions can result in batch rejection, extensive deviation investigations, or regulatory scrutiny. These issues are proportionally harmful in smaller batch sizes, as a single anomaly may compromise a significant percentage of the total batch output while consuming the same cleaning, sterilization, and validation resources as larger sets. Industries today call for single-source equipment suppliers to handle all known product types—be they liquids, suspensions, or powders—and they must handle products of varying viscosity, toxicity, shear sensitivity, and foaming. To limit batch variability, modern automation control systems must stabilize filling accuracy and minimize deviation. One effective strategy is to avoid relying on a single filling technology. For example, configuring lines to use positive displacement pumps, time‑pressure and Coriolis mass‑flow systems, powder fillers, or peristaltic pumps compatible with single‑use technology, depending on product rheology, toxicity profile, and batch strategy. To minimize variability, conduct up-front testing of each prospective customer’s primary packaging components and request samples of product formulations to ensure their systems are optimized for specific product characteristics. This approach helps ensure that the systems meet all customer user requirement specifications consistently, reducing room for error and ultimately increasing throughput. This approach also makes validation easier and consequently improves return on investment by shortening the time from equipment installation to gainful use in commercial production. In practice, engineers should precisely customize change parts and format sets for each application rather than relying on generic hardware. This approach enables rapid, repeatable changeovers across dosage forms without compromising uptime or operator safety. Digitalization, data integrity, and the future of filling lines As expectations around data integrity and process traceability increase, aseptic filling platforms must do more than run reliably at speed; they must generate complete, auditable records of critical parameters and interventions across the full production process of each batch. Real-time diagnostics, predictive preventive maintenance, and enhanced connectivity allow manufacturers to monitor equipment performance and environmental conditions continuously. What was state of the art a year ago may not be state of the art next year. Therefore, manufacturers must always be looking to advance process analytical systems, real-time diagnostics, and predictive preventive maintenance. Increased system connectivity and selective use of artificial intelligence can further support real‑time diagnostics, predictive preventive maintenance, and rapid deployment of control‑logic refinements without undermining validated states. Information technology will continue to advance at remarkable speeds, and manufacturers should always be at the forefront of innovation and product improvement. Suppliers are always working to improve their technologies in terms of mechanics, electronics, and the implementation of automation and diagnostics, all while maintaining the quality, reliability, and integrity of aseptic systems. Innovation in conjunction with commercial practicality, and a future in which germ-free environments with superior air quality are commonplace. This is what the modern filling line landscape is striving toward. About the author James E. Akers, PhD, is the president of Akers Kennedy & Associates and a technical consultant at Shibuya.
May 11th 2026

Advancing Aseptic Precision: How Modern Filling Lines Elevate Sterility, Flexibility, and Throughput

The modern landscape for biotherapeutics is undergoing a paradigm shift as advanced therapeutic modalities, such as cell and gene therapies, move from experimental stages to commercial availability. Unlike traditional biopharmaceuticals, these next-generation treatments require specialized manufacturing frameworks to ensure both biological quality and timely clinical availability. The complexity inherent in producing these therapies often leads to process unpredictability and operational hurdles that can significantly delay patient access to lifesaving treatments.1,2 To address these challenges, the industry is increasingly looking toward the integration of advanced analytical tools and artificial intelligence (AI) to facilitate more robust control and enhance overall manufacturing efficiency.3 Streamlining these intricate workflows is not merely a matter of technical interest but a necessity for managing the critical timelines associated with complex biologics. By focusing on supply chain reliability and clinical delivery, stakeholders can bridge the gap between scientific innovation and patient care.4 How does process unpredictability in manufacturing impact patient access to advanced therapies? One of the most significant barriers to the success of advanced therapies is the inherent complexity in the manufacturing process, which involves a significant amount of coordination between the patient, the treatment site, and manufacturers. In addition, there is variability between different products’ manufacturing processes, which is an administrative burden for the sites to handle as well as knowing all the different processes, says Anna Catalanotto, director, Advanced Therapy Commercial Strategy, Cardinal Health. This challenge is particularly true for autologous therapies, for which a patient’s own cells serve as the starting material.5 Manufacturing complexities in this space can create a ripple effect that touches every part of the treatment journey, Catalanotto highlights. She also emphasizes that these disruptions can have dire consequences for the individual awaiting care. Coverage and access processes that are inconsistent or delayed can lead to unpredictable patient access, which may even cause a patient to abandon their pursuit of treatment entirely, she explains. The time to manufacture these therapies and uncertainty surrounding when a patient will be ready for administration can create logistical challenges for treatment sites and manufacturers alike, Catalanotto continues. Catalanotto notes that the very ability of a patient to receive therapy is often tied to how well the manufacturer communicates the expected journey and prepares the site for potential deviations. “The manufacturing complexities can have a significant impact to patient access to these therapies,” Catalanotto says. “Whether that's from the perspective of the patient cell collection, manufacturing, or patient access, the extended time to treatment for autologous cell therapies can impact patients' ability to be treated with these therapies. Because each product may follow a distinct and complex path to the patient, maintaining clear expectations regarding timelines is vital for commercial success. Beyond the logistics, the industry must recognize that solving these delivery issues is a moral and operational imperative, according to Catalanotto. “Patient access to these cell and gene and advanced therapies is really crucial for manufacturers to solve,” she stresses. How can process analytical technologies and AI ensure robust manufacturing control? To combat the unpredictability in commercial strategists, technical experts are turning to sophisticated digital and analytical solutions. Process analytical technologies (PAT) and AI are no longer futuristic concepts but are currently being utilized to stabilize biomanufacturing operations, says Carrie Mason, head, PAT Center of Excellence, Lonza Integrated Biologics. She explains that these tools allow for a much more nuanced understanding of the data generated during a production run. Whereas traditional manufacturing often relied on "getting a result" and then making a reactive decision, the modern approach uses analytics tied to AI to build a library of information that supports predictive control. This shift allows manufacturers to categorize process characteristics with high precision, driving a philosophy of "right the first time" manufacturing, she notes. The synergy between hardware tools and software intelligence is what creates processes capable of meeting strict quality standards, Mason says. “PAT and AI really work hand in hand toward developing a robust process,” she emphasizes. By augmenting PAT tools with AI, manufacturers can enhance their process control strategies to ensure that every batch meets the necessary characteristics for clinical use. “This high level of control is essential for complex molecules that do not follow the standard production rules of simpler biologics,” Mason states. “Furthermore, the speed at which these therapies can be brought to market is directly influenced by the efficiency of these control strategies. What we are able to do with our PAT tools is augmented with advanced AI technologies in order to enhance process control strategies.” Ultimately, she explains, the goal is to reach the clinic faster while maintaining a robust manner of production that minimizes the risk of batch failure. Why is multidisciplinary collaboration essential for navigating the administrative burdens of advanced therapeutics? While technical and manufacturing improvements are critical, they exist within a broader ecosystem involving payers and health care providers. Advanced therapies often carry high up-front prices, which can lead to longer review times from insurance payers who may be concerned about the lack of long-term durability data or small clinical trial sizes, Catalanotto notes. This hesitation manifests as an administrative burden for treatment sites, which must navigate complex health plan requirements. Treatment sites often find themselves conducting single case agreements, which are one-off negotiations for coverage and payment. Such negotiations can be time-consuming and can further delay a patient's time to treatment, Catalanotto explains. She points to this administrative friction as being a significant hurdle that requires proactive education and resources for all stakeholders. The complexity of these therapies requires a level of collaboration that is rarely seen in traditional medicine, Catalanottoadds. She stresses that manufacturers must prepare to educate payers on evidence gaps and the specific end points used in clinical trials to ensure that the value of the therapy is understood. Similarly, treatment sites need support in managing workflows, storage requirements, and the payor authorization process. “That upfront collaboration between manufacturers, treatment sites, and payers really is so critical to making sure that the process for getting these patients access to therapies is as smooth and as expedited as possible, and that there is a process in place to get patients access to these therapies,” Catalanotto states. “And all stakeholders involved should have all the resources and education that they need to navigate these processes that, again, are much more complex in the cell and gene therapy space compared to other therapy types.” Without this unified approach, even the most technologically advanced manufacturing process will fail to reach the patient in a timely manner, she cautions. What role does integrated bioprocessing play in accelerating the delivery of complex molecules to the clinic? The future of manufacturing lies in the transition away from isolated, individual steps toward a more integrated and automated model, according to Mason. Integrated bioprocessing, comprising a seamless connection of various stages of production, is viewed as the key to adapting to the needs of new modalities. “As the industry moves toward more complex molecules, the methodologies used to produce them must also evolve to be more adaptive and faster. Advanced analytics and AI provide the necessary data to make this integration possible, allowing for a more streamlined path from the laboratory to the clinical setting,” Mason notes. By automating these processes, manufacturers can reduce the potential for human error and decrease the time required to move between different stages of the biomanufacturing lifecycle. This evolution is being driven by the very nature of the molecules themselves, which demand more sophisticated handling than their predecessors, Mason says. “Complex molecules and new modalities are really driving our industry to be adaptive and to drive towards a methodology that's going to get us there faster,” Mason emphasizes. The ultimate goal of this technical evolution is to reach the clinic as quickly as possible, ensuring that the innovations developed in the lab can be translated into tangible benefits for patients. It is expected that successful delivery of advanced therapies will increasingly depends on a dual strategy that consists of the technical optimization of manufacturing through AI and PAT, and the operational optimization of the commercial ecosystem through collaboration and education. By addressing process unpredictability and administrative burdens simultaneously, the industry can create a more reliable supply chain that fulfills the promise of next-generation medicine. The integration of these disparate elements, from the cleanroom to the payer's office, may ultimately define the success of advanced therapeutic delivery moving forward. References Xie W, Pedrielli G. From discovery to production: challenges and novel methodologies for next generation biomanufacturing (version 2). arXiv. 2022. doi:10.48550/arXiv.2205.03920 Morrow D, Ussi A, Migliaccio G. Addressing pressing needs in the development of advanced therapies. Front Bioeng Biotechnol. 2017;5:55. doi:10.3389/fbioe.2017.00055 Rathore AS, Sarin D. What should next-generation analytical platforms for biopharmaceutical production look like? Trends Biotechnol. 2024;42(3):282-292. doi:10.1016/j.tibtech.2023.08.008 de Bournonville S, Lambrechts T, Pinna T, Papantoniou I, Aerts JM. Streamlining data management & process analytics for the manufacturing of cell & gene therapies. Cell Gene Ther Insights. 2018;4(8):695-704. doi:10.18609/cgti.2018.068 Lamontagne A, Fesnak A. Limiting variability to achieve reproducibility in cell manufacturing. Cell Gene Ther Insights. 2020;6(10):1357-1363. doi:10.18609/cgti.2020.149
May 8th 2026

Addressing Manufacturing and Access Barriers in Advanced Therapeutics

Valerie Bandy, Tecsys
May 8th 2026

Valerie Bandy on Building Smarter Pharma Supply Chains

May 8th 2026

PharmTech Weekly Roundup-May 8, 2026

Review of SUT Adoption in Biopharma Manufacturing

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Read More
Review of SUT Adoption in Biopharma Manufacturing

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Read More
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Automating the Future of Fill/Finish

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Read More
Automating the Future of Fill/Finish

Latest Videos

Shorts

Karianne Gelinas, Lehigh Valley Economic Development Corporation
0:38
How Lehigh Valley is Prepping a Workforce for Lilly
4 months ago
by
Karianne Gelinas(+1 more)
Karianne Gelinas, Lehigh Valley Economic Development Corporation
0:43
Why Eli Lilly Chose Pennsylvania for its $3.5B Facility
4 months ago
by
Karianne Gelinas(+1 more)
Tom Sellig, Adare Pharma Solutions
0:40
The Most Important Thing for CDMOs in 2026
4 months ago
by
Tom Sellig(+1 more)
Matt Meyer, Governor, State of Delaware
0:29
How Government Leaders Are Thinking About Reshoring
4 months ago
by
Zachary Zubulake
Valerie Bandy, Tecsys
0:44
How to Approach the Balancing Act of Pharma Manufacturing
5 months ago
by
Valerie Bandy(+1 more)
Why CDMOs Must Stay Close to Industry Trends
0:20
Why CDMOs Must Stay Close to Industry Trends
6 months ago
by
Ranjit Deshmukh(+1 more)
Standardizing Processes for Faster Turnarounds
0:20
Standardizing Processes for Faster Turnarounds
6 months ago
by
Ranjit Deshmukh(+1 more)
How Counterfeiters Are Fooling The System
0:21
How Counterfeiters Are Fooling The System
7 months ago
by
Malav Parikh

More News

Drug manufacturing process. Medical pills, capsules conveyor line at a high-tech pharmaceutical plant. Pharmacology production, medicine industry. Laboratory, factory, pharmacy. Healthcare, pharma 3D | Image Credit: ©Corona Borealis - stock.adobe.com

The Future of CGMP Facilities

ByZachary Zubulake,Susan Haigney

Peter Makowenskyj, senior director of Design Consulting at G-CON, and Beata Sweryda-Krawiec, associate director at Boehringer-Ingelheim, discussed trends influencing the design of pharmaceutical manufacturing facilities during a Quick Fire Learning Lab at INTERPHEX 2026.